Recursion Pharmaceuticals Before Q4 Earnings: How to Play the StockZacks Investment Research • 02/18/25
Recursion Pharmaceuticals (RXRX) Stock Jumps 8.9%: Will It Continue to Soar?Zacks Investment Research • 02/13/25
Recursion Presents Phase 2 Data for REC-994 in CCM in Late-Breaking Oral Presentation at the International Stroke ConferenceGlobeNewsWire • 02/05/25
Recursion Pharmaceuticals (RXRX) Moves 8.9% Higher: Will This Strength Last?Zacks Investment Research • 01/23/25
Recursion Pharmaceuticals (RXRX) Rises Yet Lags Behind Market: Some Facts Worth KnowingZacks Investment Research • 01/15/25
Does Recursion Pharmaceuticals (RXRX) Have the Potential to Rally 27.96% as Wall Street Analysts Expect?Zacks Investment Research • 01/10/25
Recursion Announces Two Key Investigational Oncology Drugs Advancing to Clinical Trials, Targeting High Unmet Needs in Hematologic Malignancies, Small-Cell Lung Cancer, & MoreGlobeNewsWire • 01/07/25
Recursion Pharmaceuticals Reports Grant of Inducement Awards as Permitted by the Nasdaq Listing RulesGlobeNewsWire • 12/20/24
Recursion: Transforming Drug Discovery With Its AI-Powered Drug Development PlatformSeeking Alpha • 12/12/24
Recursion Reports Interim Phase 1 Clinical Data for REC-617 Monotherapy, a Potential Best-in-Class CDK7 Inhibitor, With Encouraging Patient Response and Favorable TolerabilityGlobeNewsWire • 12/09/24
Recursion and Exscientia, two leaders in the AI drug discovery space, have officially combined to advance the industrialization of drug discoveryGlobeNewsWire • 11/20/24